With its cancer-control effects and a different approach relative to ARPI or taxan-based chemotherapy and as a treatment delivering beta radiation to a molecular target specifically adherent to prostate cancer cells, Lu-PSMA therapy became a crucial part within the sequential therapies of mCRPC patients. The gene discussed is FOLH1; the disease is prostate cancer.